The prognostic significance of OCT4 expression in patients with prostate cancer

Takeo Kosaka, Shuji Mikami, Shunsuke Yoshimine, Yasumasa Miyazaki, Tatsuaki Daimon, Eiji Kikuchi, Akira Miyajima, Mototsugu Oya

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Accumulating evidence suggests that OCT4 participates in tumorigenicity and malignancy in human cancers. However, the prognostic significance of OCT4 expression in prostate cancer (PCa) or predictive significance of OCT4 in docetaxel sensitivity in castration-resistant prostate cancer (CRPC) remains unclear. The aim of this study was to assess the prognostic value of OCT4 expression in PCa. We retrospectively analyzed the clinical records and evaluated the OCT4 expression in 205 patients with PCa who underwent radical prostatectomy. We examined the change of OCT4 expression in 3 patients with CRPC who underwent transurethral resection for local progression before and after docetaxel chemotherapy. OCT4 expression was significantly associated with higher pathological T stage (P <.001). The 5-year prostate-specific antigen recurrence-free survival rate was 56.8% in patients with higher OCT4 expression and 90.6% in patients with lower OCT4 expression (P <.001). Multivariate analysis revealed that high OCT4 expression was an independent prognostic indicator of prostate-specific antigen recurrence (P <.001). Elevated strong OCT4 expression in residual CRPC cells after docetaxel chemotherapy was observed in all CRPC patients, compared with before chemotherapy in corresponding specimens. Higher OCT4 expression represents a clinically relevant predictor of patient prognosis in PCa and may be a new biomarker that will provide additional prognostic information in CRPC when treated with docetaxel.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalHuman Pathology
Volume51
DOIs
Publication statusPublished - 2016 May 1

Fingerprint

docetaxel
Prostatic Neoplasms
Castration
Prostate-Specific Antigen
Drug Therapy
Recurrence
Prostatectomy
Neoplasms
Multivariate Analysis
Survival Rate
Biomarkers

Keywords

  • Castration-resistant prostate cancer
  • Docetaxel resistance
  • Immunohistochemistry
  • OCT4
  • Prostate cancer
  • PSA recurrence

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

The prognostic significance of OCT4 expression in patients with prostate cancer. / Kosaka, Takeo; Mikami, Shuji; Yoshimine, Shunsuke; Miyazaki, Yasumasa; Daimon, Tatsuaki; Kikuchi, Eiji; Miyajima, Akira; Oya, Mototsugu.

In: Human Pathology, Vol. 51, 01.05.2016, p. 1-8.

Research output: Contribution to journalArticle

Kosaka, Takeo ; Mikami, Shuji ; Yoshimine, Shunsuke ; Miyazaki, Yasumasa ; Daimon, Tatsuaki ; Kikuchi, Eiji ; Miyajima, Akira ; Oya, Mototsugu. / The prognostic significance of OCT4 expression in patients with prostate cancer. In: Human Pathology. 2016 ; Vol. 51. pp. 1-8.
@article{7d1bddc6a7cc489ea6a011a423522a2c,
title = "The prognostic significance of OCT4 expression in patients with prostate cancer",
abstract = "Accumulating evidence suggests that OCT4 participates in tumorigenicity and malignancy in human cancers. However, the prognostic significance of OCT4 expression in prostate cancer (PCa) or predictive significance of OCT4 in docetaxel sensitivity in castration-resistant prostate cancer (CRPC) remains unclear. The aim of this study was to assess the prognostic value of OCT4 expression in PCa. We retrospectively analyzed the clinical records and evaluated the OCT4 expression in 205 patients with PCa who underwent radical prostatectomy. We examined the change of OCT4 expression in 3 patients with CRPC who underwent transurethral resection for local progression before and after docetaxel chemotherapy. OCT4 expression was significantly associated with higher pathological T stage (P <.001). The 5-year prostate-specific antigen recurrence-free survival rate was 56.8{\%} in patients with higher OCT4 expression and 90.6{\%} in patients with lower OCT4 expression (P <.001). Multivariate analysis revealed that high OCT4 expression was an independent prognostic indicator of prostate-specific antigen recurrence (P <.001). Elevated strong OCT4 expression in residual CRPC cells after docetaxel chemotherapy was observed in all CRPC patients, compared with before chemotherapy in corresponding specimens. Higher OCT4 expression represents a clinically relevant predictor of patient prognosis in PCa and may be a new biomarker that will provide additional prognostic information in CRPC when treated with docetaxel.",
keywords = "Castration-resistant prostate cancer, Docetaxel resistance, Immunohistochemistry, OCT4, Prostate cancer, PSA recurrence",
author = "Takeo Kosaka and Shuji Mikami and Shunsuke Yoshimine and Yasumasa Miyazaki and Tatsuaki Daimon and Eiji Kikuchi and Akira Miyajima and Mototsugu Oya",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.humpath.2015.12.008",
language = "English",
volume = "51",
pages = "1--8",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - The prognostic significance of OCT4 expression in patients with prostate cancer

AU - Kosaka, Takeo

AU - Mikami, Shuji

AU - Yoshimine, Shunsuke

AU - Miyazaki, Yasumasa

AU - Daimon, Tatsuaki

AU - Kikuchi, Eiji

AU - Miyajima, Akira

AU - Oya, Mototsugu

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Accumulating evidence suggests that OCT4 participates in tumorigenicity and malignancy in human cancers. However, the prognostic significance of OCT4 expression in prostate cancer (PCa) or predictive significance of OCT4 in docetaxel sensitivity in castration-resistant prostate cancer (CRPC) remains unclear. The aim of this study was to assess the prognostic value of OCT4 expression in PCa. We retrospectively analyzed the clinical records and evaluated the OCT4 expression in 205 patients with PCa who underwent radical prostatectomy. We examined the change of OCT4 expression in 3 patients with CRPC who underwent transurethral resection for local progression before and after docetaxel chemotherapy. OCT4 expression was significantly associated with higher pathological T stage (P <.001). The 5-year prostate-specific antigen recurrence-free survival rate was 56.8% in patients with higher OCT4 expression and 90.6% in patients with lower OCT4 expression (P <.001). Multivariate analysis revealed that high OCT4 expression was an independent prognostic indicator of prostate-specific antigen recurrence (P <.001). Elevated strong OCT4 expression in residual CRPC cells after docetaxel chemotherapy was observed in all CRPC patients, compared with before chemotherapy in corresponding specimens. Higher OCT4 expression represents a clinically relevant predictor of patient prognosis in PCa and may be a new biomarker that will provide additional prognostic information in CRPC when treated with docetaxel.

AB - Accumulating evidence suggests that OCT4 participates in tumorigenicity and malignancy in human cancers. However, the prognostic significance of OCT4 expression in prostate cancer (PCa) or predictive significance of OCT4 in docetaxel sensitivity in castration-resistant prostate cancer (CRPC) remains unclear. The aim of this study was to assess the prognostic value of OCT4 expression in PCa. We retrospectively analyzed the clinical records and evaluated the OCT4 expression in 205 patients with PCa who underwent radical prostatectomy. We examined the change of OCT4 expression in 3 patients with CRPC who underwent transurethral resection for local progression before and after docetaxel chemotherapy. OCT4 expression was significantly associated with higher pathological T stage (P <.001). The 5-year prostate-specific antigen recurrence-free survival rate was 56.8% in patients with higher OCT4 expression and 90.6% in patients with lower OCT4 expression (P <.001). Multivariate analysis revealed that high OCT4 expression was an independent prognostic indicator of prostate-specific antigen recurrence (P <.001). Elevated strong OCT4 expression in residual CRPC cells after docetaxel chemotherapy was observed in all CRPC patients, compared with before chemotherapy in corresponding specimens. Higher OCT4 expression represents a clinically relevant predictor of patient prognosis in PCa and may be a new biomarker that will provide additional prognostic information in CRPC when treated with docetaxel.

KW - Castration-resistant prostate cancer

KW - Docetaxel resistance

KW - Immunohistochemistry

KW - OCT4

KW - Prostate cancer

KW - PSA recurrence

UR - http://www.scopus.com/inward/record.url?scp=84978873489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978873489&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2015.12.008

DO - 10.1016/j.humpath.2015.12.008

M3 - Article

C2 - 27067776

AN - SCOPUS:84978873489

VL - 51

SP - 1

EP - 8

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -